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We verified the diagnostic and prognostic role of a simplified
immunophenotypic classification (IC) in a series of 258 patients
(M/F: 1.4; median age: 64 years; median follow-up: 64 months;
75 deaths) with mature B cell lymphoid leukemias (MBC-LL) for
whom no histopathological diagnosis was available because of
minimal or no lymph node involvement. The IC was based on
the reactivity of three pivotal immunophenotypic markers: CD5,
CD23 and SIg intensity. On the basis of different expression
patterns, we identified four diagnostic clusters (C) charac-
terized by distinct clinico-biological features and different pro-
gnoses: C1 (149 patients) identified most classical B cell
chronic lymphocytic leukemias (CLL-type cluster;
SIgdim/CD5+/CD23+); C2, 38 patients whose clinico-hematolog-
ical characteristics were intermediate between C1 and C3 (CLL-
variant cluster; SIgbright/CD5+/CD23+/−or SIgdim/CD5−/−/CD23
indifferent); C3 (16 patients) most situations consistent with
mantle cell lymphoma in leukemic phase (MCL-type cluster;
SIgbright/CD5+/CD23−); and C4, 55 cases, most of whom were
consistent with leukemic phase lymphoplasmacytic/splenic
marginal zone lymphomas (LP/S-type cluster;
SIgbright/CD5−/+/CD23 indifferent). At univariate survival analy-
sis, prognosis worsened from C1 to C4, C2 and C3 (P = 0.0001),
and this was maintained at multivariate analysis (P = 0.006),
together with CD11c expression (P = 0.0043), age at diagnosis
(cut-off 70 years; P = 0.0008) and platelet count (cut-off 140 ×
109/l; P = 0.0034). Besides recognising the two well-known situ-
ations of classic B-CLL and MCL, our IC identified situations
with distinct prognostic and/or clinical behaviors.
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Introduction
Mature B cell lymphoid leukemias (MBC-LL) are a frequent
and biologically heterogeneous group of neoplastic disorders
characterized by different clinical behaviors and therapeutic
responses, whose ﬁrst-line deﬁnition is based on cell mor-
phology, immunophenotype ﬁndings and clinical presen-
tation.1 Histopathological analysis is fundamental for attribu-
ting the leukemic picture to a speciﬁc clinico-pathologic
entity according to the REAL/WHO classiﬁcation,2 but is not
always available because of the absence of easily biopsied
lymphoid tissue. The development of cytogenetic and molecu-
lar studies has allowed the identiﬁcation of speciﬁc markers
for only a subset of these diseases, leaving the diagnostic
evaluation to ﬂow cytometric analysis. A number of important
immunophenotypic diagnostic scoring systems have been pro-
posed, but they were validated on the basis of cytomorpholog-
ical data and not veriﬁed in terms of prognostic impact.3,4
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For these reasons, and bearing in mind the relatively high
frequency of MBC-LL patients in whom histopathological data
cannot be obtained at diagnosis, there is a need for simpliﬁed
immunophenotypic criteria that could be useful in clinical
practice and also applied in centers without highly specialized
laboratories. In this study, we evaluated the reactivity of major
immunological markers in a series of MBC-LL patients with
the aim of investigating their accuracy in distinguishing patho-
logical situations whose biological and clinical characteristics
overlap to a certain degree. On the basis of this preliminary
analysis, we developed an immunophenotypic classiﬁcation
(IC) involving three pivotal markers (CD5, CD23 and SIg
intensity) and tested its role in deﬁning the diagnosis and
prognosis of this MBC-LL subset.
Materials and methods
Patients
The study involved 258 patients with mature B cell leukemia
and minimal or absent superﬁcial lymph node involvement
(152 males and 106 females; ratio = 1.4; median age at diag-
nosis 64 years, range 30–93) who were evaluated at diagnosis
and characterized by means of ﬂow cytometry at the Marcora
Center for Blood Diseases between 1993 and 1999. All of
them had light chain restricted CD19-positive lymphocytosis
(4 × 109/l); those with CD10-positive leukemic phase fol-
licular lymphomas were excluded. The cut-off point for lym-
phocyte doubling time (LDT) was 12 months, which was not
evaluable in 97 patients, six of whom were followed up for
less than 12 months and 91 received early treatment because
of active disease without any sign of lymphocyte duplication.
The Binet staging system could not be used because we
selected cases without any signiﬁcant superﬁcial lymph
adenopathies.
At the time of analysis, the median follow-up was 64
months (range 3-96). Seventy-ﬁve patients had died: 52 of dis-
ease, 17 due to unrelated problems, and six because of second
solid tumors. One hundred and seventy patients had received
chemotherapy from the start of the study. First-line therapy
was relatively homogenous and mainly consisted of alkylat-
ing agents.
Morphological analysis
Peripheral blood ﬁlms stained with May–Gru¨nwald-Giemsa
were morphologically evaluated taking into account the FAB
criteria1 and the WHO revised REAL classiﬁcation.2 The cases
were grouped as follows: (1) typical chronic lymphocytic leu-
kemia (CLL: 90% small lymphocytes); (2) lymphoplasmocy-
toid lymphoma/immunocytoma (LPIC) in leukemic phase; (3)
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splenic lymphoma with villous lymphocytes (SLVL); (4) hairy
cell leukemia (HCL); (5) heterogeneous/non-CLL forms. This
last group included situations (prolymphocytic leukemia,
mixed cell CLL, mantle cell lymphoma (MCL), polymorphic
forms) whose morphological discrimination is often quite dif-
ﬁcult and poorly reproducible between assessors. The diag-
nostic deﬁnition and morphological classiﬁcation was sup-
ported by bone marrow histology in 218 cases. The
histological pattern of bone marrow inﬁltration (diffuse or not
diffuse) was also recorded.
Immunophenotype analysis
For the immunological, molecular and cytogenetic analyses,
mononuclear cell suspensions were obtained from hep-
arinized peripheral blood by means of Ficoll–Hypaque gradi-
ent centrifugation. The samples underwent direct and indirect
immunoﬂuorescence staining with monoclonal antibodies
(MoAbs), and the surface immunoglobulins (SIg) were charac-
terized as previously described.5 The MoAbs used were anti-
CALLA FITC for CD10; anti-Leu1-FITC, anti-Leu12-PerCP and
anti-Leu20-PE for respectively CD5, CD19 and CD23; anti-
IL2-R-FITC for CD25; anti- Leu-M5-PE for CD11c; puriﬁed
anti-integrin 3 for CD49c (Becton Dickinson, Mountain
View, CA, USA); anti-integrin 4-FITC for Cd49d
(Immunotech SA, Marseilles, France); anti-human CD1c-FITC
(Ancell, Bayport, MN, USA); anti-CD103-FITC (Immuno Qual-
ity products, Groningen, The Netherlands); and anti-human
FMC7-FITC (DAKO, Glostrup, Denmark). The second-step
reagent for indirect immunoﬂuorescence was goat anti-mouse
Ig-FITC (Becton Dickinson).
Dual or three-color immunophenotyping was always per-
formed. The controls for these experiments included irrelevant
isotype-matched MoAbs and FITC, PE or PerCP mouse Ig.
FITC-conjugated F(ab’)2 fragments of rabbit Ig (DAKO) were
used for SIg analysis. The cells were examined using a FAC-
Scan ﬂow cytometer (Becton Dickinson), with the data being
acquired and analyzed by means of CELLQuest software
(Becton Dickinson). The expression of each marker was calcu-
lated in terms of percentage reactivity on CD19+ cells and
graded as follows: 0 or − (20% of CD19+ cells), 1 or ±
(20% and 60%) and 2 or + (60%). The intensity of SIg
and FMC7 was evaluated on the basis of ﬂuorescence inten-
sity and two expression levels were so deﬁned: dim indicated
a certain degree of overlapping between the ﬂuorescence his-
tograms of the positive cells and those of the cells used as
negative controls (the difference between the median ﬂuor-
escence channel of the positive and negative cells was
between 100 and 390: mean ± s.d. = 292 ± 49); bright indi-
cated that no overlapping was demonstrable (difference
between 400 and 750: mean ± s.d. = 514 ± 96). When the
ﬂuorescence intensity was evaluated in terms of molecules of
equivalent soluble ﬂuorochrome (MESF) (Quantum Kits, Flow
Cytometry Standards, San Juan, CA, USA), dim was deﬁned
as a ﬂuorescence intensity 9 × 103 MESF, and bright one of
9 × 103 MESF.
Cytogenetic analysis
The karyotype analyses were performed by means of QFD
binding as previously reported,6 and the chromosomes were
classiﬁed according to the International System for Human
Cytogenetic Nomenclature (ISCN).7 A clone was deﬁned as
two cells having the same structural rearrangement or a gain
of the same chromosome, or three cells with the loss of the
same chromosome.
Bcl-1 and bcl-6 analyses
Only the patients in clusters C2 and C3 were analyzed for
bcl-1 on the grounds of our previous data showing no involve-
ment of this gene in classical CLL,8 and bcl-6 was evaluated
only in the cases falling into cluster C4 because of the lack of
data concerning the frequency of its rearrangement in patients
whose phenotype consists of bright SIg and low CD5 and
CD23 expression. The analysis was performed as previously
reported.6,9
Statistical methods
Descriptive statistics were calculated for the quantitative
(mean, standard deviation, minimum, maximum and median
in the case of asymmetric distributions) and qualitative vari-
ables (absolute and relative frequencies) with their pertinent
95% conﬁdence intervals. The diagnostic classes were com-
pared using Kruskal–Wallis non-parametric analysis of vari-
ance for quantitative variables, and the chi-square test for
qualitative variables. The agreement between the different
monoclonal antibody reactivities was calculated according to
Cohen’s k.10 The signiﬁcance level of the multiple compari-
sons was corrected using Bonferroni’s procedure.11 The fol-
low-up was truncated at 8 years in order to obtain reliable
estimates of the cumulative probability of no evolution or sur-
vival according to Kaplan and Meier;12 the differences
between the survival curves were evaluated using the log-rank
test. The best subset of prognostic factors was obtained using
a Cox proportional hazards regression model following a
backward procedure; the goodness of ﬁt was checked by
means of stratiﬁed analysis.13
Results
Immunophenotype and diagnostic cluster distribution
The heavy SIg chain was  in 147/258 cases (57.0%; 95%
conﬁdence intervals, CI: 50.7–63.1%) and  in 70 (27.1%;
95% CI: 21.8–33.0%); , ,  chain expression was observed
in respectively, 18 (7.0%; 95% CI: 4.2–10.8%), 13 (5.0%;
95% CI: 2.7–8.4%) and 10 cases (3.9%; 95% CI: 1.9–7.0%).
The proportion of SIg 	 cases vs SIg
 cases was 1.79. Dim SIg
ﬂuorescence was observed in 153 cases (59.3%; 95% CI:
53.0–65.3%). The reactivity of the individual markers is
shown in Figure 1. CD5 reactivity = 2 was observed in 75.9%
of the cases (95% CI: 70.3–81.0%), and CD5/CD23 co-
expression in 187/258 cases (72.5%; 95% CI: 66.6–77.8%),
inversely correlated with the intensity of SIg ﬂuorescence (143
of the 163 CD5+/CD23+ cases were SIg dim; 87.7%). CD49c
was highly expressed in 180/245 cases (73.4%; 95% CI: 67.5–
78.9%), whereas CD1c reactivity was often = 0 (133/238;
55.9%; 95% CI: 49.3–62.3%). FMC7, CD11c, CD25 and
CD49d reactivity = 2 was observed in about 50% of cases.
The intensity of FMC7 ﬂuorescence was evaluated in 219
cases: it was dim in 96 (43.8%; 95% CI: 37.2–50.7%) and
bright in 123 (56.2%; 95% CI: 49.3–62.8%).
On the basis of the known diagnostic role of CD5
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Figure 1 Individual marker reactivities of peripheral blood lym-
phocytes in 258 cases of mature B cell lymphoid leukemia. Percent-
age of cases by degree of reactivity: white, reactivity = 1; black,
reactivity = 2.
expression, CD5-CD23 co-expression and SIg reactivity pat-
terns,14,15 and by analyzing the relative frequencies of the
tested MoAb reactivity in our series, we identiﬁed four clusters
of patients. The two situations consistent with a diagnosis of
‘classical’ CLL (SIgd/CD5+/CD23+) or a leukemic form of MCL
(SIgb/CD5+/CD23+) were, respectively, classiﬁed as CLL-type
(C1: 149 patients) and MCL-type clusters (C3: 16 patients).
The remaining clusters included less deﬁned situations: a
group of 38 patients with a CLL variant pattern because of the
persistence of CD5 reactivity = 2 and CD23 reactivity = 1 or
2 in the presence of bright SIg (SIgb/CD5+/CD23+/±), or the per-
sistence of dim SIg in the presence of CD5 reactivity = 0 or 1
(SIgd/CD5−/±/CD23 indifferent), was deﬁned as the CLL-variant
type (C2); ﬁnally, 55 patients with a phenotype characterized
by CD5 reactivity = 0 or 1 and bright SIg (SIgb/CD5−/±/CD23
indifferent) were considered to be affected by leukemic phase
of lymphoplasmocytic/splenic marginal zone lymphomas, and
were classiﬁed as the LP/S-type (C4).
There were no signiﬁcant between-cluster differences in
terms of SIg classes, but the  chain was more frequent in C4;
the proportion of SIg 	 cases vs SIg
 cases increased from C1
to C4 (1.73, 2.1, 2.0 and 2.5), but this trend was not signiﬁ-
cant. CD1c, CD49d and FMC7 were less expressed in C1 than
in the other clusters (P = 0.001), and the intensity of FMC7
ﬂuorescence in C1-positive cases was always less (P =
0.0001). Grade 2 CD49c reactivity was more observed in C1
than in the other clusters (P = 0.001), and CD11c reactivity
was more frequent in C1 and C4 than in C2 and C3 (P =
0.001). There was no signiﬁcant between-cluster difference in
CD25 expression (Figure 2).
Cytomorphology
As shown in Table 1, a typical CLL-like morphology was
observed in 155 cases (60.0%; 95% CI 53.8–66.1%), and was
prevalent in cluster C1 (80% of the cases, as against 39% in
C2, 44% in C3 and 25% in C4); non-CLL forms (103 cases,
40.0%) were signiﬁcantly more frequent in C4 (P = 0.0001).
A high number of LPIC and SLVL morphologies were observed
in C4; HCL-like forms were observed only in C4.
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Figure 2 Distribution of individual marker reactivities of periph-
eral blood lymphocytes in 258 cases of mature B cell lymphoid leuke-
mias on the basis of our diagnostic cluster deﬁnition (C1–C4); white,
reactivity = 1; black, reactivity = 2.
Clinico-hematological features
The median age of the 258 patients was 64 years (range 30–
94), and the male/female ratio 1.43. Table 2 shows their most
relevant clinico-hematological characteristics by ﬂow cyto-
metric clusters. There were signiﬁcant between-cluster differ-
ences in splenomegaly, hemoglobin, platelet counts, 2
microglobulin and LDH serum levels, the pattern of bone mar-
row inﬁltration, patient status and the need for therapy. HCV
antibodies were tested in 142 patients at diagnosis: the 11
positive cases (8%) included 5/21 C4 patients.
The median time from diagnosis to therapy was 6 months
in the patients as a whole: 11 months in C1, 2 months in C2,
1 month in C3, and 3 months in C4. The relationship between
disease-related and overall deaths in the four clusters was
17/29 in C1, 12/16 in C2, 9/9 in C3 and 14/21 in C4. LDT
was (12 months in 73.3% (95% CI: 67.8–79.9%) of the
patients and (12 months in 26.7% (95% CI: 20.1–34.2%); the
cluster distribution is shown in Table 2.
Karyotype
Karyotype abnormalities increased from C1 to C3, but the dif-
ferences were not signiﬁcant (Table 3). Chromosome 12 tri-
somies and partial deletions involving chromosomes 11 and
13 were mainly observed in C1 and C2. Structural abnormali-
ties of chromosomes 14 and 17 were more frequent in C4
than in C1. The most frequent karyotpe abnormalities in C3
were t(11;14) and chromosome 14 alterations, but the limited
number of cases does not allow any statistical evaluation.
Molecular ﬁndings
Bcl-1 rearrangements were found in C2 (3/33 cases) and
mainly in C3 (9/16 cases; P = 0.001). In C2, the two bcl-1
rearranged cases were SIgbright/CD5+/CD23+/±. Six of the 11
rearranged cases were cytogenetically evaluated: four had the
expected t(11;14) translocation, one had a complex karyotype
with chromosome 14 abnormalities and one had a normal
karyotype (Table 3). None of the C4 patients showed any bcl-
6 rearrangement.
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Table 1 Peripheral blood morphology (number of cases and percentages) of the whole series and in relation to the immunophenotype clusters
(C1–C4)
Whole series % C1 % C2 % C3 % C4 %
No. of cases 258 149 38 16 55
CLL 155 60.0 119 79.9 15 39.5 7 43.7 14 25.5
Non-CLL 103 40.0 30 20.1 23 60.5 9 56.3 41 74.5
LPIC 31 6 6 1 18
SLVL 12 1 5 0 6
HCL 2 0 0 0 2
Heterogeneous 58 23 12 8 15
CLL, typical chronic lymphocytic leukemia; LPIC, lymphoplasmocytoid lymphoma/immunocytoma; SLVL, splenic lymphoma with villous
lymphocytes; HCL, hairy cell leukemia.
Table 2 Clinico-hematological data at diagnosis in the whole series and by immunophenotype clusters (C1–C4)
Variables Total cases Cluster 1 Cluster 2 Cluster 3 Cluster 4 P
No. of cases 258 149 38 16 55
Age 70 years 67 (25.9) 35 (23.5) 9 (23.7) 7 (43.7) 16 (29.1) NS
Male/Female 1.43 1.36 1.92 1.28 1.39 NS
Splenomegalya 105 (40.6) 31 (20.1) 21 (55.3) 10 (62.5) 43 (78.2) 0.001
Hemoglobin 11 g/dl 35 (13.5) 8 (5.4) 6 (15.8) 6 (37.5) 15 (27.3) 0.001
Platelets 140 × 109/l 72 (27.9) 30 (20.1) 17 (44.7) 7 (43.7) 18 (32.7) 0.006
Serum monoclonal component 63 (24.4) 29 (19.5) 10 (26.3) 4 (25.0) 20 (36.4) NS
LDH 460 U/l 47 (18.2) 15 (10.1) 7 (18.4) 9 (56.2) 16 (29.1) 0.001
Lymphocytes 20 × 109/l 75 (29.0) 43 (28.9) 10 (26.3) 7 (43.7) 15 (27.3) NS
Cytomorphology
CLL 155 (60.0) 119 (79.9) 15 (39.4) 7 (43.7) 14 (25.4)
CLL variant 25 (9.6) 12 (80.5) 7 (18.4) 0 (0) 6 (10.9) 0.001
not CLL 78 (30.2) 18 (12.1) 16 (42.1) 9 (56.2) 35 (63.6)
Overall deaths 75 (29.0) 29 (19.4) 16 (42.1) 9 (56.2) 21 (38.1) 0.001
Chemotherapy 170 (65.8) 84 (56.4) 25 (65.7) 14 (87.5) 47 (85.4) 0.001
No. of cases 161 111 20 4 26
LDTb 12 months; No. of cases 43 (26.7) 29 (26.1) 5 (25) 2 (50.0) 7 (26.9) NS
No. of cases 164 101 22 10 31
Serum 2 microglobulin 2.6 g/ml 77 (46.9) 36 (35.6) 14 (63.6) 7 (70) 20 (64.5) 0.003
No. of cases 218 122 35 14 47
Diffuse bone marrow histology 74 (33.9) 33 (27.0) 13 (37.1) 9 (64.3) 19 (40.4) 0.025
No. of cases 220 132 33 8 47
Abnormal karyotype 75 (34.1) 39 (29.5) 14 (42.4) 5 (62.5) 17 (36.2) NS
No. of cases 142 95 15 6 21
HCV antibody positivity 11 (8.4) 6 (6.3) 0 (0) 0 5 (23.8) NS
NS, not significant.
aManual and/or ecographic.
bLDT, lymphocyte doubling time (not evaluated in 97 patients receiving chemotherapy in first year from diagnosis or with a follow-up of
less than 12 months).
Percentages in parentheses.
Survival analysis, prognostic variables and prognostic
stratiﬁcation
Table 4 shows the 5-year cumulative survival probability and
95% CI, and the signiﬁcance of the variables having a prog-
nostic impact on survival at univariate analysis. In addition
to age, the clinico-hematological variables were spleen size,
hemoglobin, platelet count, serum LDH, 2 microgobulin
level, the bone marrow inﬁltration pattern and karyotype.
There was no statistical signiﬁcance in terms of gender, the
absolute number or morphology of lymphocytes, or the pres-
ence of a monoclonal component or HCV antibodies. The
probability of survival was highest in the patients with SIg dim
and 0 or 1 CD49d/CD1c reactivity, and lowest in those with
0 CD11c/CD49c reactivity, and 0 or 1 CD23 reactivity. No
statistically signiﬁcant association with survival was found in
the case of CD25, CD19+CD5 or FMC7 expression. With ref-
erence to the immunophenotype diagnostic clusters, survival
signiﬁcantly worsened from C1 to C4, C2 and C3 (Figure 3).
The poor prognostic signiﬁcance of the C2 designation was
maintained when the three bcl-1 rearranged cases were
excluded from the analysis (data not shown).
Multivariate statistical analyses were performed using Cox’s
model considering the different clinical occasions on which
prognosis could be assessed (Table 5). In our selected series,
when the clinico-hematological variables were recorded, age,
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Whole series % C1 % C2 % C3 % C4 %
No. of cases 220 132 33 8 47
Normal 145 65.9 93 70.4 19b 57.6 3 37.5 30 63.8
Abnormal 75 34.1 39 29.6 14 42.4 5 62.5 17 36.2
trisomy 12 17 22.6 12 30.7 3 21.4 1 20.0 1 5.9
del (11q) 10 13.3 6 15.3 3 21.4 0 0 1 5.9
del (13q) 4 5.3 4 10.2 0 0 0 0 0 0
t (11;14) 5 6.6 1 2.5 2a 14.2 2a 40.0 0 0
14 alterations 13 17.3 2 5.1 2 14.2 2c 40.0 7 41.1
17 alterations 10 13.3 4 10.2 1 7.1 0 0 5 29.4
Other abnormalities 16 21.3 10 25.6 3 21.4 0 0 3 17.6
abcl-1 rearranged.
bOne case was bcl-1 rearranged.
cOne case was bcl-1 rearranged.
platelet count and spleen size made up the most parsimonious
subset of variables related to survival. In a sub-sample of 220
patients with available cytogenetic and bone marrow his-
tology patterns, a further model was obtained in which age at
diagnosis and spleen size retained a signiﬁcant independent
association with survival (RR 2.11, 95% CI: 1.20–3.69, P =
0.009; RR 2.28, 95% CI: 1.18–3.36, P = 0.003), together with
an abnormal karyotype (RR 1.99, 95% CI: 1.32–3.91, P =
0.001). When the immunophenotype features were con-
sidered alone, the degree of CD11c expression and the inten-
sity of SIg ﬂuorescence remained independent prognostic fac-
tors, but when the immunophenotype clusters were included
in the model, SIg ﬂuorescence lost its statistical signiﬁcance
as a result of redundancy. Similar results were obtained using
a more parsimonious model that pooled clusters 2 and 3.
Finally, in a combined clinico-immunophenotype model, age
at diagnosis, platelet count, CD11c expression and cluster
classiﬁcation retained their prognostic signiﬁcance. On the
basis of these variables, the survival analysis of the prognostic
score (PS) classes obtained using the Cox models could be
clearly differentiated because of the combination of the rela-
tive risks. Figure 4 shows the survival curves of the three prog-
nostic classes (PS 2.3, 2.3 3, 3 9).
Discussion
The REAL/WHO classiﬁcation has greatly improved the clin-
ico-pathological, immunophenotypic, genetic and molecular
characterization of lymphomas and leukemias. However, the
integration of these ﬁndings with lymphoid tissue analysis is
not always possible in the case of MBC-LL for various reasons:
(1) the absence of easily accessible pathological tissue; (2) the
decision to avoid lymph node biopsy in particular clinical
situations (eg elderly patients, comorbidity); and (3) the fre-
quent practice of avoiding invasive diagnostic interventions
in cases that are considered to be sufﬁciently well deﬁned
immunocytomorphologically (eg classic CLL). On the basis of
these considerations, the immunophenotypic analysis of per-
ipheral or bone marrow cells plays a pivotal diagnostic role.
From this point of view, various scoring systems have been
proposed over the last few years. The ﬁrst was suggested by
Matutes et al,3 and was based on the reactivity of CD5, CD23,
FMC7 and the intensity of SIg and CD22 expression; it cor-
rectly diagnosed 87% of CLLs, 89% of other B cell leukemias
and 72% of NHLs in leukemic phase in terms of their corre-
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spondence with FAB cytomorphology. In 1995, Salomon-
Nguyen et al16 proposed another scoring system (based on
CD22, CD23 and FMC7 reactivity, and SIg intensity) aimed
at distinguishing the rare subsets of CD5− CLL (less than 10%
of CLL) and B-PLL from typical CD5+ CLL. Moreau et al4 have
recently proposed a revised version of their scoring system3
in which CD22 is replaced by CD79b, which proved to be
negative in most cases of CLL and positive in most other B
cell disorders.17 Although very important, these studies have
only been validated on the basis of morphological data and
not extensively veriﬁed in a clinical context.
In our study, we made an in-depth analysis of a large num-
ber of newly diagnosed MBC-LLs with minimal or absent
lymph-node involvement with the aims of: (1) selecting com-
monly used lymphoid markers to include in a simpliﬁed IC
that would be useful in identifying in MBC-LL spectrum not
only cases consistent with a diagnosis of CLL or MCL, but
also other forms possibly characterized by a distinct clinical
behavior; and (2) evaluating the prognostic role of the system
as an independent or dependent variable when considered
together with clinico-hematological prognostic features. Our
simpliﬁed IC was formulated using the relative frequencies of
the reactivity of the tested MoAbs, while taking into account
the consistent immunophenotype pattern of typical CLLs and
MCLs based on CD5 and CD23 reactivity and the pattern of
SIg expression. The combined reactivity of these three markers
identiﬁed four diagnostic clusters. This phenotypic classi-
ﬁcation did not include FMC7, CD22 and CD79b reactivity
because their reactivity was not negligible in C1 (respectively
40%, 49% and 64%, data not shown), although they were
preferentially expressed in C2, C3 and C4. It is interesting to
note that the intensity of their ﬂuorescence seemed to be more
useful because it was always low in FMC7- and CD79b-posi-
tive cases in C1, and there was a close correlation between
CD79b and SIg ﬂuorescence intensity (data not shown).
Although our IC is simpler than those previously proposed
(in so far as it is based on fewer MoAb markers),3,4,16 it still
seems to be highly capable of dividing the MBC-LL series into
different pathological entities characterized by recurrent clin-
ico-hematological features and a different clinical course. C1
(CLL-type cluster) identiﬁed classical CLL cases, 80% of which
had a CLL morphology. The frequently indolent behavior of
CLL was well represented by the favorable clinical character-
istics of a large number of patients (little organ involvement,
no cytopenia and a long time from diagnosis to therapy), and
this cluster also included a larger number of patients with the
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Table 4 Univarate survival analysis in patients with mature B cell lymphoid leukemias
Variable No. of cases 5-year cumulative P
survival probability (95% CI)
Whole series 258 0.73 (0.67–0.69)
SIg fluorescence intensity:
Dim 153 0.84 (0.78–0.90)
Bright 105 0.56 (0.46–0.66) 0.0001
CD11c expressiona
1+2 128 0.87 (0.81–0.93)
0 122 0.58 (0.48–0.68) 0.0001
CD23 expressiona
2 185 0.79 (0.73–0.85)
0+1 73 0.58 (0.44–0.72) 0.0017
CD49d expressiona
0+1 113 0.86 (0.79–0.93)
2 138 0.61 (0.51–0.71) 0.0003
CD49c expressiona
1+2 191 0.76 (0.70–0.82)
0 54 0.58 (0.42–0.74) 0.0143
CD1c expressiona
0+1 146 0.79 (0.71–0.87)
2 92 0.62 (0.50–0.74) 0.0080
Immunophenotypic clusters:
C1 149 0.84 (0.78–0.90)
C4 55 0.69 (0.55–0.83)
C2 38 0.52 (0.32–0.72)
C3 16 0.22 (0.00–0.56) 0.0001
Age at diagnosis (years)
70 191 0.80 (0.74–0.86)
70 67 0.50 (0.36–0.64) 0.0001
Spleen size
Normal 153 0.84 (0.78–0.90)
Increased 105 0.56 (0.46–0.66) 0.0001
Hemoglobin (g/dl)
11 223 0.77 (0.71–0.83)
11 35 0.47 (0.27–0.67) 0.0011
Platelet count (/(l)
140 000 186 0.80 (0.74–0.86)
140 000 72 0.51 (0.37–0.65) 0.0001
Serum L.D.H. (/U.I.)
460 207 0.78 (0.72–0.84)
460 47 0.52 (0.36–0.68) 0.0008
Beta-2 microglobulin (g/dl)
2.6 87 0.98 (0.95–1.00)
2.6 77 0.83 (0.74–0.92) 0.0001
Bone marrow infiltration pattern
Not diffuse 144 0.81 (0.73–0.89)
Diffuse 74 0.61 (0.52–0.70) 0.0003
Cytogenetic analysis
Normal karyotype 145 0.82 (0.75–0.92)
Abnormal karyotype 75 0.60 (0.48–0.72) 0.0008
aMonoclonal antibody reactivity: 0: 20% of CD19+ cells; 1: 20% and 60%; 2: 60%.
karyotype abnormalities most frequently described in CLL
(trisomy 12 and partial deletion of chromosome 11). C3 (MCL-
type cluster) clearly identiﬁed the forms of MCL-related leuke-
mia because the patients in this cluster showed the highest
frequency of the karyotypic t(11;14) and genetic alterations
(bcl-1 rearrangement) consistent with this type of NHL, and
splenomegaly, anemia and thrombocytopenia were parti-
cularly frequent. C2 (CLL-variant cluster) identiﬁed patients
whose immunophenotype has been generically reported as
being consistent with a diagnosis of ‘variant’ CLL. The patients
in this cluster more frequently showed splenomegaly, throm-
bocytopenia, anemia, a shorter time to treatment start, and
karyotypic abnormalities and atypical cytomorphologies con-
sistent with a higher degree of malignancy. In this cluster bcl-
1 rearrangement was sporadic, conﬁrming the independence
of C2 from C3/typical MCL forms. These data support the
hypothesis that C2 score identiﬁed a ‘variant’ CLL charac-
terized by a distinctive clinical behavior. C4 (LP/S-type
cluster) included a heterogeneous group of cases charac-
terized by bright SIg and little or no CD5 reactivity. Their mor-
phologies were prevalently of the non-CLL type (LPIC and
SLVL, even including the only two cases of HCL) and the
involvement of chromosome 14 and 17 was remarkably fre-
quent. The frequent splenic involvement (78% of cases) sug-
gested the possibly common splenic origin of these forms,
whose subtypes could be better identiﬁed using an extended
MoAb panel (including CD103 and CyIg).
Our IC also seems to recognize clinical entities with differ-
ent outcomes as both the univariate and multivariate analyses
showed that the patients in C3 and C2 had a signiﬁcantly
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Figure 3 Actuarial survival probability in 258 patients with mature
B cell lymphoid leukemias by diagnostic cluster attribution: 149
patients were classiﬁed in cluster 1 (C1), 38 in cluster 2 (C2), 16 in
cluster 3 (C3) and 55 in cluster 4 (C4).
Table 5 Multivariate (Cox) analysis of the parameters statistically signiﬁcant at univariate analysis
Variables Relative risk 95% CI P
Basic clinical model
Age at diagnosis: 70 vs 70 years 2.54 1.56–4.14 0.0002
Platelet count: 140 000 vs 140 000/l 2.02 1.17–3.51 0.0120
Spleen size: increased vs normal 1.77 1.01–3.09 0.0443
Basic immunophenotype model
CD11c expression: 0 vs 1+2a 2.56 1.49–4.39 0.0006
SIg fluorescence: bright vs dim 2.30 1.39–3.82 0.0013
Immunophenotype with clusters model
CD11c expression: 0 vs 1+2a 2.56 1.49–4.39 0.0013
Immunophenotype cluster 0.0001
Cluster 4 vs 1 1.55 0.84–2.85
Cluster 2 vs 1 2.75 1.43–5.29
Cluster 3 vs 1 6.10 2.64–14.07
Combined clinical and immunophenotype model
Age at diagnosis: 70 vs 70 years 2.44 1.45–4.11 0.0008
Platelet count: 140 000 vs 140 000/l 2.15 1.29–3.59 0.0034
CD11c expression: 0 vs 1+2a 2.28 1.30–4.01 0.0043
Immunophenotype cluster 0.0060
Cluster 4 vs 1 1.20 0.64–2.27
Cluster 2 vs 1 2.46 1.24–4.89
Cluster 3 vs 1 3.63 1.51–8.70
aMonoclonal antibody reactivity: 0: 20% of CD19+ cells; 1: 20% and 60%; 2: 60%.
worse prognosis than those in C4 and C1. Given the small
number of C3 cases, we could not distinguish the prognostic
value of a C3 designation vs bcl-1 rearrangement or t(11;14),
which are generally accepted as deﬁning characteristics of
MCL, in establishing the best predictor of a poor outcome.
Interestingly, CD11c expression retained its independent
prognostic role when cluster attribution was included in the
multivariate analysis. This was conﬁrmed by the prognostic
scoring analysis of various Cox models, which showed that
the combined evaluation of the degree of CD11c expression
and cluster attribution was the best immunophenotypical
means of prognostic stratiﬁcation. The prognostic role of
CD11c has been previously described, and its greater
expression in the clusters with a better prognosis (C1 and C4)
not only conﬁrms our previous clinical observations,5 but is
also in line with the results of Eistere et al18 and Sembries et
al19 concerning B-CLLs. Our results also conﬁrm the obser-
vations of Sembries et al19 regarding the correlation between
Leukemia
Figure 4 Cumulative survival probability curves obtained using
Cox’s combined ‘clinical and immunophenotype with cluster’ model
(age70 years, platelet count140 000/l, CD11c negativity, cluster
2 or 3). (a) 1 unfavorable prognostic factor; (b) two unfavorable
prognostic factors; (c) 3 unfavorable prognostic factors.
the presence of the 11q deletion and low CD11c expression:
in C1, 11q partial deletions were more frequently observed in
CD11c-negative cases (7/27 vs 2/40, P = 0.036; data not
shown). Perhaps CD11c low expression could postulate the
presence of karyotypic alterations, one of these is 11q partial
deletion, which modifying the expression of different adhesion
molecules or tumour-suppressor genes, are important for
development and progression of this subset of MBC-LL. In
relation to the prognostic role of immunophenotypic markers,
such as bright SIg and CD23 reactivity 0 or 1, whose presence
negatively inﬂuenced survival, our data conﬁrm the previous
observations of Geisler et al.20 Moreover, there are interesting
similarities in terms of clinical presentation (high frequency of
splenomegaly) and prognosis between our LP/S-type cluster
and a subset of SIgbright/CD5−/CD23− cases reported in the
same paper. Cartron et al21 made the same observations,
although they did not draw any deﬁnite conclusions concern-
ing prognosis. Tefferi et al22 did not conﬁrm the prognostic
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role of bright SIg light chain expression, but their series was
too small. Recently, in a small series of classic B-CLL patients,
Hulkkonen et al23 observed an interesting association between
certain phenotypic characteristics and speciﬁc karyotypic
alterations (eg trisomy 12 and enhanced CD27 and SIgM	
expression, or the deletion of chromosome arm 11q and
enhanced expression of CD45RO). We did not measure these
markers in our series and thus cannot validate these data.
However, they support our ﬁndings concerning CD11c
expression and the presence of the 11q deletion and suggest
a possible relationship between speciﬁc karyotypic alterations
and the expression of some particular antigens. We ﬁnally
evaluated the prognostic impact of our IC in relation to the
immunophenotype markers and clinico-hematological vari-
ables in this selected series of MBC-LL patients. Multivariate
analysis showed that only the proposed cluster classiﬁcation,
CD11c expression, age more than 70 years and thrombocyto-
penia retained their prognostic signiﬁcance. In this combined
prognostic model, although the clinico-hematological features
are important because they relate to tumor burden or patient
status, our simpliﬁed IC seems to be capable of identifying the
different entities from a biological point of view.
In conclusion, our immunophenotype classiﬁcation is not
only a simpliﬁed and efﬁcacious means of deﬁning different
MBC-LL entities, but may also play an important role in terms
of prognostic stratiﬁcation. In particular it identiﬁes not
infrequent situations, such as those falling in the CLL-var and
LP/S-type clusters (C2 and C4), that have particular prognostic
and/or clinical behaviors.
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